Who we are

• Dominique co-founded OSE in April 2012 with Emile Loria. She was Chief Executive Officer (CEO) of OSE from 2012 to April 2018, then Chairwoman of the Board of Directors from April 2018 to June 2024.
• In parallel with her mandates, she led OSE’s strategy and development from 2012 to October 2024 (retirement), with an extension until January 2025 (as a consultant) to oversee the drafting of the results of the phase 2 study on Lusvertikimab.

See Our collective track record at the head of OSE

• Before OSE, Dominique was CEO until 2011 of BioAlliance Pharma (today Valerio Therapeutics), a biotech company she founded in 1997 and took public in 2005.
• From 1982 to 1997, within Hoechst Marion Roussel (today Sanofi), she managed R&D and pharmaceutical marketing activities, from research to market (Immunology, Endocrinology, Inflammation, Infectious diseases, Oncology).
• Dominique has served on the Boards of several biotech companies: Abivax, Carthera, Sensorion, Theranexus, and Theradiag. She was a member of the High Council for Science and Technology.
• She holds an MD, specializing in immunology (Université René Descartes, Paris V).
• She is a Knight of the Legion of Honour (2008) and an Officer of the National Order of Merit (2011).

• Emile originated the OSE project in 2011 and 2012 through the acquisition from Takeda of the product OSE 2101 (now Tedopi®) and all assets relating to epitopes.
• He co-founded OSE in April 2012 with Dominique Costantini. He served as non-executive Chairman of the Board of Directors until April 2018. In this role, he brought OSE his extensive international expertise in biotech, immuno-oncology, and partnerships.

See Our collective track record at the head of OSE

• Emile has long experience in biotech in France and the United States. He founded, led, or chaired the following companies: Portable Genomics (California), Affichem and Antialis (France), Epimmune (which merged with Immuno-Designed Molecules, California), Biovector Therapeutics (France) ) and Dendrogenix (Belgium)..
• At MS Medical Synergy, his consulting firm, Emile contributed to the strategy and development of Cygnus Therapeutics Systems, of BioAlliance Pharma (now Valerio Therapeutics), where he met Dominique Costantini, as well as Teratech and Biovector Therapeutics.
• Previously, Emile worked for pharmaceutical companies (Sanofi, Ciba-Geigy, Hoffman-La Roche-Kontron). He conducted research activities at the National Cancer Institute and at Institut du Cancer et d’Immunogénétique.
• Emile holds an MD (Université Paris Diderot).

• Alexis joined Dominique and Emile in September 2013 as Chief Financial Officer and Chief Operating Officer.
• He became Director and Deputy CEO in charge of finance, business development, and operations in May 2016, then CEO in April 2018. développement et des opérations en mai 2016, puis directeur général (CEO) en avril 2018.
• For personal reasons, he stepped down from his CEO position and Board mandate in January 2022.

See Our collective track record at the head of OSE

• Since leaving OSE, Alexis has co-founded two biotech companies, Inside Therapeutics and OWL Lifesciences, where he chairs the Strategic Committees.
• Before OSE, he was Head of Management Control, then South America Director at Guerbet (medical imaging). Previously, he worked within Hoechst Marion Roussel (now Sanofi) in Japan, in the Baltic countries, then across the entire Eastern Europe zone.
• Through his experiences in France and internationally, Alexis has built major expertise in growth strategies, fundraising, licensing agreements, leading multicultural teams, and improving operational management.
• He is a graduate of EDHEC and holds an Executive MBA from Imperial College London.

• Markus has over thirty years of experience in the biotechnology sector. He is recognized for his entrepreneurial spirit and for his outstanding achievements.
• As Chief Business Officer of ChemoCentryx, he led the product development and key aspects supporting the commercialization of TAVNEOS® across seven market countries. He also led multi-party negotiations with major pharmaceutical companies and secured agreements preserving commercial rights and development control in the United States.
• He also played a key role in the acquisition of ChemoCentryx by Amgen for $4 billion, representing a 116% premium, after having raised $435 million at the IPO, $138 million through private equity fundraising, and over $250 million in non-dilutive financing.
• Prior to ChemoCentryx, Markus was Vice-President of Business Development at Advanced Inhalation Research (AIR). There, he negotiated an exclusive agreement with Eli Lilly and built a strategic alliance with GlaxoSmithKline, obtaining an upfront payment of $125 million.
• Markus holds an MBA from Harvard Business School and a PhD in Pharmaceutical Sciences from J.W. Goethe University in Germany.

• Jonathan has more than 35 years of experience in the biotech sector as an entrepreneur, investor, consultant, executive committee member, and board member. His international experience covers the United States, Asia, the European Union, China, and Russia.
• Jonathan is CEO of Ultra High Materials (materials science, USA). Previously, he was President of Biovotion AG (medical devices, Switzerland), Partner at St Clair Commons (medical campus), and Managing Director of the Cleveland Clinic’s venture capital fund. He began his career at Bain & Co.
• Jonathan founded, developed, took public, or took part in the acquisition of several biotechnology and biopharmaceutical companies: Human Genome Sciences, Molecular Devices, Gene Networks…
• He played a key role in negotiating strategic partnerships with pharmaceutical companies such as GlaxoSmithKline, Sanofi, Schering Plough (now Merck), Takeda, Novo Nordisk, Roche, and Pfizer, thereby securing hundreds of millions of dollars in funding to support research, development, and clinical trials.
• He holds an MBA from Harvard Business School and a BA in Human Biology with honors (cum laude) and distinction from Stanford University.

• Marc currently supports numerous biotech companies as an advisor, board member, and investor.
• Between 2015 and 2023, he created and managed two biotech investment funds within Financière Arbevel. There, he completed 11 investments and 2 exits: TransCure bioServices sold to Cathay Capital (4x) in early 2022 and Imactis sold to GE Healthcare (2x) in early 2023.
• Previously, he was Chief Financial Officer of Cellectis, where he raised €120 million and prepared the Nasdaq listing. He also led and turned around CYTOO.
• • A graduate of HEC in 1992, Marc began his career in organizational consulting (Bossard Consultants), then in strategy consulting (Arthur D. Little). He founded his first biotech company, BioProtein Technologies, in 1998.

• Shihong has extensive experience in all matters relating to intellectual property, particularly in biotech, medical research, and the pharmaceutical industry.
• She is currently an intellectual property advisor to NPS and Torrey Pines Law Group, as well as to the LARTA Institute (California).
• Shihong managed, for over 20 years, a major intellectual property portfolio at the Office of Innovation and Commercialization (OIC) at the University of California, San Diego (UCSD). In this influential position, she oversaw the commercial development of UCSD’s discoveries.
• Previously, at Pfizer (Agouron, acquired by Warner-Lambert, then by Pfizer), Shihong made significant contributions to antiviral and anticancer drug R&D through her work on clinical trials and FDA regulatory approvals.
• Shihong holds a PhD in Pharmaceutical Chemistry from the University of Kansas.